Wang Xiaoyan, Shen Shourong, Li Nan, Li Yu
Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Feb;35(2):171-5. doi: 10.3969/j.issn.1672-7347.2010.02.014.
To evaluate the therapeutic effect of Ursodeoxycholi acid on the treatment of liver cirrhosis with hepatitis B.
Eighty-four patients with liver cirrhosis were randomly divided into 2 groups:42 to the treatment group who were given oral capsules of Ursodeoxycholi acid combined with reduced glutathione,and the other 42 to the control group who received Yinzhihuang intravenously, combined with reduced glutathione. Therapeutic efficacy,liver function and its normalization rate,and score of Child-pugh-Turcotte (CPT)were observed after 4 week treatment and 8 week treatment.
The therapeutic efficacy had no significant difference between the treatment group and the control group (P>0.05). Compared with the control group, the values of gamma-glutamyl transpeptidase (gamma-GT), alkaline phosphatase (AKP) and globulin(GLO) of the treatment group decreased more significantly (P<0.05), and the normalization rates of gamma-GT and AKP in the treatment group was significantly higher than that in the control group at 8 week. The decreased levels of total bilirubin (TBIL) and direct bilirubin(DBIL) were not significantly different between the 2 groups (P>0.05). At 4 week the decrease level of ALT in the 2 groups was similar (P>0.05), while at 8 week the values of ALT reduced more significantly than that of the control group(P<0.05). The score of CPT of the 2 groups were not different after 4 week and 8 week treatment (P>0.05).
Ursodeoxycholi acid can obviously decrease the values of gamma-GT, AKP and GLO in liver cirrhosis with hepatitis B, which may be related to Ursodeoxycholi acid relieving the injury of bile duct and enhancing biliary transport.
